Tweenvest Stocks

Halberd Corporation (OTCPK: HALB)

Health Care · Biotechnology · US

$0.00

+100.00% today · -3.4% 1Y

Halberd Corporation (OTCPK: HALB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.49M and employs 3 people.

Over the last twelve months the share price has lost 3.4%, trading between 0.00 and 0.00.

Tweenvest scores Halberd Corporation across four factors: quality 3/100, value 46/100. Its strongest factor is value.

HALB price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$1.49M
Revenue (TTM)
$6.94K
P/E
—
EPS
-0.00
Dividend yield
—
Beta (5Y)
0.11
52-week high
$0.00
52-week low
$0.00
Avg volume (3M)
—
Shares outstanding
747.30M
Employees
3
Next earnings
—

About Halberd Corporation

Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.

ISIN
US4053311092
Founded
2009
Listed since
Sep 25, 2012
Exchange
Pink Sheets LLC
Currency
USD
CompanyMarket capPriceDay
Neural Therapeutics Inc.CNSX: NURL$1.80MCA$0.02-25.00%
Respiratorius AB (publ)XSAT: RESP$1.72MSkr2.19+0.92%
BioXcel Therapeutics, Inc.OTCPK: BTAI.Q$1.63M$0.05+35.42%
Curis, Inc.NasdaqCM: CRIS$1.54M$0.68-7.37%
BioSenic S.A.ENXTBR: BIOS$1.47M€0.00-9.09%
Silexion Therapeutics CorpNasdaqCM: SLXN$1.45M$0.23-12.43%
Hexima LimitedASX: HXL$1.44MAU$——
Protagenic Therapeutics, Inc.OTCPK: PTIX$1.40M$0.77-15.34%

Browse every Biotechnology company →

Figures last refreshed Oct 4, 2026.